We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+8.25%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.7B
AUM Growth
+$337M
Cap. Flow
+$308M
Cap. Flow %
18.12%
Top 10 Hldgs %
39.64%
Holding
351
New
78
Increased
102
Reduced
60
Closed
41

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$40.1M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$37.1M
3
DNLI icon
Denali Therapeutics
DNLI
+$36.2M
4
INSP icon
Inspire Medical Systems
INSP
+$27.3M
5
VIR icon
Vir Biotechnology
VIR
+$21.9M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$39.4M
2
RAPT
RAPT Therapeutics
RAPT
+$17.3M
3
CDTX
Cidara Therapeutics
CDTX
+$13.2M
4
FULC icon
Fulcrum Therapeutics
FULC
+$10.4M
5
ABUS icon
Arbutus Biopharma
ABUS
+$9.98M

Sector Composition

Rank Sector Weight
1 Healthcare 88.42%
2 Miscellaneous 9.68%
3 Financials 1.51%
4 Technology 0.08%
5 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABUS icon
26
Arbutus Biopharma
ABUS
$1B
$14.1M 0.83%
3,133,175
-2,281,934
-42% -$9.98M
AMLX icon
27
Amylyx Pharmaceuticals
AMLX
$3.87B
$13.9M 0.82%
1,000,604
+110,248
+12% +$1.55M
CLDX icon
28
Celldex Therapeutics
CLDX
$3.07B
$13.6M 0.8%
427,816
-218,951
-34% -$5.97M
TSHA icon
29
Taysha Gene Therapies
TSHA
$1.88B
$13.3M 0.78%
2,979,429
+483,620
+19% +$2.25M
XENE icon
30
Xenon Pharmaceuticals
XENE
$5.81B
$13.3M 0.78%
228,899
+24,930
+12% +$1.15M
STRO icon
31
Sutro Biopharma
STRO
$339M
$13.1M 0.77%
524,441
+457,364
+682% +$8.27M
RVMD icon
32
Revolution Medicines
RVMD
$44.6B
$13M 0.77%
133,893
-11,186
-8% -$1.13M
ELVN icon
33
Enliven Therapeutics
ELVN
$4.24B
$12.9M 0.76%
329,540
+299,540
+998% +$8.3M
CGON icon
34
CG Oncology
CGON
$6.59B
$12.6M 0.74%
185,699
-72,440
-28% -$4.1M
BIL icon
35
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$46.7B
$12.4M 0.73%
135,585
– –
ESTA icon
36
Establishment Labs
ESTA
$2.11B
$12.1M 0.71%
213,473
+42,051
+25% +$2.87M
REPL icon
37
Replimune Group
REPL
$1.46B
$12.1M 0.71%
1,582,987
+341,665
+28% +$2.61M
IVA
38
Inventiva
IVA
$1.11B
$12.1M 0.71%
2,174,398
-535,448
-20% -$3.26M
IONS icon
39
Ionis Pharmaceuticals
IONS
$10.1B
$12M 0.71%
160,338
+13,208
+9% +$1.04M
NKTR icon
40
Nektar Therapeutics
NKTR
$2.48B
$11.6M 0.68%
161,252
+89,221
+124% +$5.08M
IKT icon
41
Inhibikase Therapeutics
IKT
$336M
$11.1M 0.65%
6,606,572
-1,457,377
-18% -$2.59M
SPRY icon
42
ARS Pharmaceuticals
SPRY
$586M
$10.9M 0.64%
1,361,536
+991,967
+268% +$9.51M
TERN
43
CALL
DELISTED
Terns Pharmaceuticals
TERN
$10.5M 0.62%
+200,000
New +$8.21M
HLXC
44
Helix Acquisition Corp III
HLXC
$238M
$10.3M 0.61%
+1,000,000
New +$10.2M
OVID icon
45
Ovid Therapeutics
OVID
$547M
$10.1M 0.59%
4,544,113
+259,113
+6% +$463K
OKUR
46
OnKure Therapeutics
OKUR
$153M
$10.1M 0.59%
2,434,941
+1,420,783
+140% +$4.39M
REGN icon
47
Regeneron Pharmaceuticals
REGN
$81.8B
$9.39M 0.55%
12,154
+103
+0.9% +$78.9K
MLTX icon
48
MoonLake Immunotherapeutics
MLTX
$1.28B
$8.52M 0.5%
+457,137
New +$7.57M
LXEO icon
49
Lexeo Therapeutics
LXEO
$399M
$8.42M 0.5%
1,467,350
+74,189
+5% +$526K
IRD
50
Opus Genetics
IRD
$307M
$8.41M 0.5%
1,849,004
+1,809,004
+4,523% +$6.26M
1
2
3 4 5

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, ADAR1 Capital Management held 351 positions worth $1.7B, up 25% from $1.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

ADAR1 Capital Management deployed $308M of net new capital in Q1 2026, opening 78 new positions and adding to 102 existing holdings. Its largest new stake was Beam Therapeutics: 1,446,375 shares worth $34.5M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $10.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2026 buy was Beam Therapeutics: 1,446,375 shares worth $34.5M.
  • ADAR1 Capital Management added most to Crinetics Pharmaceuticals in Q1 2026, an estimated $37.1M increase.
  • ADAR1 Capital Management's biggest Q1 2026 reduction was Fulcrum Therapeutics, cutting an estimated $10.4M.
  • ADAR1 Capital Management fully exited Avidity Biosciences in Q1 2026, selling an estimated $39.4M.
  • ADAR1 Capital Management's ten largest holdings make up 40% of its $1.7B portfolio in Q1 2026.
  • ADAR1 Capital Management opened 78 new positions and closed 41 in Q1 2026.
  • ADAR1 Capital Management's portfolio value rose 25% quarter-over-quarter to $1.7B.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.